Tools for Practice Outils pour la pratique


#313 Gastrointestinal bleeding – Does tranexamic acid halt it or not?


CLINICAL QUESTION
QUESTION CLINIQUE
Does tranexamic acid reduce mortality or other clinically significant outcomes in gastrointestinal bleeds?


BOTTOM LINE
RÉSULTAT FINAL
In acute gastrointestinal bleeds, tranexamic acid does not reduce mortality, transfusions, surgical interventions, or intensive care stay compared to placebo and should not be routinely used.



CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session



EVIDENCE
DONNÉES PROBANTES
  • High quality, international, randomized controlled trial (RCT) of 12009 patients with significant acute (signs of shock or likely to require transfusion, endoscopy or surgery) gastrointestinal bleed (90% upper).Patients (mean age 58 years, 64% males) randomized to 1-gram intravenous tranexamic acid (TXA), followed by 3g infusion over 24-hours or placebo. Outcomes not statistically different at 28 days:
    • All-cause mortality: 9.5% versus 9.2% placebo
    • Death from gastrointestinal bleeding: 4.2% versus 4.4% placebo
    • Transfused units of whole blood or red cells: 2.8 versus 2.9 placebo
    • Proportion requiring surgical intervention 87.6% versus 87.5% placebo
    • Days in intensive care: 1.8 days versus 2.0 placebo
    • Thromboembolic events: 1.4% versus 1.2% placebo.
    • Limitations: Other care provided was not explicitly stated and likely differed between countries.
  • Systematic review done prior to above RCT (8 studies, 1701 patients)2 found 5-day mortality benefit with TXA but is limited by:
    • Small number of patients (total ~15% of above RCT),
    • Benefit disappeared when patients lost to follow up were conservatively analyzed.
Context
  • Peptic ulcer disease, gastritis, esophageal varices and Mallory-weiss tears are the most common etiologies of upper gastrointestinal bleeds.3,4
  • Upper gastrointestinal bleed mortality has been decreasing since late 20th century; is currently ~2%.3
  • Proton pump inhibitors given prior to endoscopy may decrease the need for endoscopic treatments but have not been shown to decrease mortality.5
  • Restrictive transfusion strategies (example transfusing hemoglobin at 70-80 g/L versus 90-100 g/L) does not negatively affect mortality or other outcomes.6
  • Performing gastroscopies for upper gastrointestinal bleeds within 24 hours has similar outcomes as performing them within 6 hours.7


Trudy mcnabb April 28, 2022

Helpful

Raghad Al-Tameemy April 29, 2022

Informative

Philippe ROHE May 9, 2022

no interest of CYKLOKAPRON in UGB

Gilbert Bretecher November 6, 2022

no benefit from Tranexamic acid in upper GI bleeds

Gilbert Bretecher November 6, 2022

endoscopy needed within 24 hours of GI bleed

Gilbert Bretecher November 6, 2022

PPI’s help before endoscopy in GI bleeds


Latest Tools for Practice
Derniers outils pour la pratique

#369 Remind me, do medications that target brain amyloid improve my dementia?

Are amyloid-targeting monoclonal antibodies safe and effective for mild cognitive impairment or Alzheimer’s dementia?
Read Lire 0.25 credits available Crédits disponibles

#368 Sodium Restriction in Heart Failure: Beneficial or pouring salt in the wound?

Does sodium restriction improve outcomes in patients with chronic heart failure?
Read Lire 0.25 credits available Crédits disponibles

#367 Oral Calcitonin Gene-related Peptide Antagonists: A painfully long name for the acute treatment of migraines

What are the risks and benefits of ubrogepant for the acute treatment of episodic migraines?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session


Author(s)
Auteur(s)
  • Jennifer Young MD CCFP-EM
  • Michael Kolber BSc MD CCFP MSc

1. HALT-IT Trial Collaborators. Lancet. 2020; 95:1927-36.

2. Bennett C, Klingenberg SL, Langholz E, et al. Cochrane Database Syst Rev. 2014; 11:CD006640.

3. Tielleman T, Bujanda D, Cryer B. Gastrointest Endosc Clin N Am. 2015; 25: 415–428.

4. Thiebaud P, Yrodanov Y, Galimard J et al. Scand J Trauma Resus Emerg Med. 2017; 25:78.

5. Kanno T, Yuan Y, Tse F, et al. Cochrane Database Syst Rev. 2022; 1: CD005415.

6. Carson JL, Stanworth SJ, Roubinian N, et al. Cochrane Database Syst Rev. 2016; 10: CD002042.

7. Merola E, Michielan A, de Pretis G. Intern Emerg Med. 2021; 16:1331–1340.

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.